Comparative Pharmacology
Head-to-head clinical analysis: UVADEX versus ZYTIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UVADEX versus ZYTIGA.
UVADEX vs ZYTIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Uvadex, when combined with UVA light, intercalates into DNA and upon UVA activation forms covalent cross-links with pyrimidine bases, thereby inhibiting DNA synthesis and inducing apoptosis in activated T-cells.
Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor that selectively inhibits the enzyme CYP17 (17α-hydroxylase/C17,20-lyase). This inhibition blocks androgen production in the testes, adrenal glands, and prostate tumor tissue.
200 mcg/mL solution administered via intravenous injection 0.017 mL/kg (3.4 mcg/kg) 30 minutes prior to each photopheresis treatment, given on two consecutive days every 2–4 weeks.
1000 mg orally once daily on an empty stomach, at least 1 hour before or 2 hours after a meal, in combination with prednisone 5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 8-20 hours) following intravenous administration; clinically, this supports daily dosing schedules.
The terminal elimination half-life of abiraterone is approximately 12 hours (range 9–18 hours) following oral administration, supporting twice-daily dosing.
Primarily renal excretion of unchanged drug (approximately 70% within 24 hours) and metabolites; minor fecal elimination (<10%).
Abiraterone is primarily eliminated via hepatic metabolism with less than 1% excreted unchanged in urine. Approximately 88% of a radiolabeled dose is recovered in feces (mainly as metabolites) and about 5% in urine.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent